CONFERENCE UPDATE: EHA 2021
A+AVD as a desirable treatment option for patients with previously untreated stage III/IV CHL: A 5-year update of the phase 3 ECHELON-1 study
24 Sep 2021
Related Articles
CONFERENCE UPDATE: EHA 2021
A+AVD as a desirable treatment option for patients with previously untreated stage III/IV CHL: A 5-year update of the phase 3 ECHELON-1 study